Koers AVAX Technologies, Inc. Other OTC
Aandelen
AVXT
US0534953056
Biotechnologie & Medisch Onderzoek
Omzet 2009 | 399K 367K | Omzet 2010 | 142K 131K | Marktkapitalisatie | 6,29 mln. 5,79 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2009 | -19 mln. -17,48 mln. | Nettowinst (verlies) 2010 | -12 mln. -11,04 mln. | EV/omzet 2009 | 69 x |
Nettoschuld 2009 | 3,23 mln. 2,97 mln. | Nettoschuld 2010 | 3,1 mln. 2,85 mln. | EV/omzet 2010 | 65,9 x |
K/w-verhouding 2009 |
-1,24
x | K/w-verhouding 2010 |
-1,03
x | Werknemers | - |
Dividendrendement 2009 * |
-
| Dividendrendement 2010 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Adele Sommerfeld
CEO | Chief Executive Officer | - | 19-10-15 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Andrew W. Dahl
CHM | Chairman | 79 | 01-09-99 |
Adele Sommerfeld
CEO | Chief Executive Officer | - | 19-10-15 |
Bruno Maruzzo
BRD | Director/Board Member | 71 | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+33,63% | 50,85 mld. | |
-0,09% | 42,82 mld. | |
+49,62% | 42,03 mld. | |
-4,96% | 29,55 mld. | |
+11,18% | 26,11 mld. | |
-21,95% | 19,13 mld. | |
+8,61% | 13,05 mld. | |
+28,31% | 12,16 mld. | |
+24,73% | 12,08 mld. |